Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,599.50
Bid: 1,604.00
Ask: 1,604.50
Change: 4.50 (0.28%)
Spread: 0.50 (0.031%)
Open: 1,600.50
High: 1,612.50
Low: 1,591.00
Prev. Close: 1,595.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

13 Dec 2023 15:30

RNS Number : 6543W
GSK PLC
13 December 2023

GSK plc (the 'Company')

Transaction notification

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Emma Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.4015

9 (partnership shares)

£14.4015

9 (matching shares)

d)

Aggregated information

Aggregated volume Price

18 Ordinary Shares

£14.4015

e)

Date of the transaction

2023-12-11

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Julie Brown

b)

Position/status

Chief Financial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.4015

9 (partnership shares)

£14.4015

9 (matching shares)

d)

Aggregated information

Aggregated volume Price

18 Ordinary Shares

£14.4015

e)

Date of the transaction

2023-12-11

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

James Ford

b)

Position/status

SVP and Group General Counsel, Legal and Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.4015

9 (partnership shares)

£14.4015

9 (matching shares)

d)

Aggregated information

Aggregated volume Price

18 Ordinary Shares

£14.4015

e)

Date of the transaction

2023-12-11

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Sally Jackson

b)

Position/status

SVP, Global Communications and CEO Office

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.4015

8 (partnership shares)

£14.4015

8 (matching shares)

d)

Aggregated information

Aggregated volume Price

16 Ordinary Shares

£14.4015

e)

Date of the transaction

2023-12-11

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

David Redfern

b)

Position/status

President Corporate Development

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.4015

9 (partnership shares)

£14.4015

9 (matching shares)

d)

Aggregated information

Aggregated volume Price

18 Ordinary Shares

£14.4015

e)

Date of the transaction

2023-12-11

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Regis Simard

b)

Position/status

President, Global Supply Chain

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.4015

9 (partnership shares)

£14.4015

9 (matching shares)

d)

Aggregated information

Aggregated volume Price

18 Ordinary Shares

£14.4015

e)

Date of the transaction

2023-12-11

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Phil Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.4015

9 (partnership shares)

£14.4015

9 (matching shares)

d)

Aggregated information

Aggregated volume Price

18 Ordinary Shares

£14.4015

e)

Date of the transaction

2023-12-11

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Deborah Waterhouse

b)

Position/status

CEO, ViiV Healthcare and President, Global Health, GSK

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.4015

9 (partnership shares)

£14.4015

9 (matching shares)

d)

Aggregated information

Aggregated volume Price

18 Ordinary Shares

£14.4015

e)

Date of the transaction

2023-12-11

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Victoria Whyte

b)

Position/status

Company Secretary

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.4015

8 (partnership shares)

£14.4015

8 (matching shares)

d)

Aggregated information

Aggregated volume Price

16 Ordinary Shares

£14.4015

e)

Date of the transaction

2023-12-11

f)

Place of the transaction

London Stock Exchange (XLON)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHFFEFSDEDSEEE
Date   Source Headline
24th Apr 20185:41 pmRNSTrelegy Ellipta expanded US COPD indication
20th Apr 20183:15 pmRNSDirector/PDMR Shareholding
20th Apr 20183:15 pmRNSDirector/PDMR Shareholding
19th Apr 20187:00 amRNSIMPACT study shows benefits of Trelegy Ellipta
18th Apr 201810:34 amRNSLandmark IMPACT study to be published in NEJM
18th Apr 201810:02 amRNSIMPACT study shows benefits of Trelegy Ellipta
17th Apr 20181:47 pmRNSDirector/PDMR Shareholding
17th Apr 20181:36 pmRNSDirector/PDMR Shareholding
17th Apr 20181:30 pmRNSDirector/PDMR Shareholding
17th Apr 20181:24 pmRNSDirector/PDMR Shareholding
17th Apr 20181:20 pmRNSDirector/PDMR Shareholding
13th Apr 20183:50 pmRNSDirector/PDMR Shareholding
13th Apr 20183:44 pmRNSDirector/PDMR Shareholding
13th Apr 201811:32 amRNSNotice of GM
12th Apr 20183:04 pmRNSDirector/PDMR Shareholding
3rd Apr 20184:14 pmRNSTotal Voting Rights
29th Mar 20181:00 pmRNSNotice of AGM
27th Mar 20187:00 amRNSGSK agrees to acquire CH business from Novartis
23rd Mar 201811:21 amRNSViiV - CHMP positive opinion for Juluca in Europe
23rd Mar 20187:44 amRNSUpdate regarding Pfizer Inc. Consumer Healthcare
23rd Mar 20187:00 amRNSShingrix approved in Europe and Japan
19th Mar 20187:00 amRNSGSK 2017 Form 20-F
13th Mar 20182:10 pmRNSAnnual Financial Report
12th Mar 20184:30 pmRNSDirector/PDMR Shareholding
8th Mar 20188:00 amRNSGSK announces labelling update to Relvar Ellipta
5th Mar 20185:01 pmRNSViiV Healthcare announces new dolutegravir data
5th Mar 20182:47 pmRNSNucala OSMO study presented at AAAAI-WAO congress
5th Mar 201812:04 pmRNSDirector/PDMR Shareholding
2nd Mar 20181:11 pmRNSDirector/PDMR Shareholding
1st Mar 201811:16 amRNSTotal Voting Rights
22nd Feb 20184:54 pmRNSDirector/PDMR Shareholding
20th Feb 20181:17 pmRNSDirector/PDMR Shareholding
20th Feb 20181:16 pmRNSDirector/PDMR Shareholding
20th Feb 20181:15 pmRNSDirector/PDMR Shareholding
19th Feb 20186:12 pmRNSDirector/PDMR Shareholding
16th Feb 20185:29 pmRNSDirector/PDMR Shareholding
16th Feb 20185:25 pmRNSDirector/PDMR Shareholding
16th Feb 201811:20 amRNSDirector/PDMR Shareholding
15th Feb 20186:09 pmRNSDirector/PDMR Shareholding
15th Feb 20185:57 pmRNSDirector/PDMR Shareholding
15th Feb 20185:53 pmRNSDirector/PDMR Shareholding
14th Feb 20189:00 amRNSGSK submits landmark IMPACT data - Trelegy Ellipta
13th Feb 20184:44 pmRNSDirector/PDMR Shareholding
12th Feb 20182:43 pmRNSDirector/PDMR Shareholding
12th Feb 201812:47 pmRNSDirector/PDMR Shareholding
8th Feb 20189:31 amRNSViiV Healthcare launches new two-drug HIV study
8th Feb 20187:00 amRNSViiV files patent infringement litigation
7th Feb 20181:19 pmRNSDirector/PDMR Shareholding
7th Feb 201812:01 pmRNSFinal Results
7th Feb 20189:04 amRNSGSK's Bexsero FDA Breakthrough Therapy Designation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.